Methylene Blue

Pediatric Emergency Care - Tập 37 Số 9 - Trang 474-477 - 2021
Renita S. Pushparajah Mak1, Erica L. Liebelt1,2
1Assistant Professor of Pediatrics (Pushparajah Mak) and Professor of Pediatrics (Liebelt), University of Arkansas for Medical Sciences
2Medical and Research Director (Liebelt), Clinical Pharmacology and Toxicology, and Associate Medical Director (Liebelt), Arkansas Poison Drug and Information Center, University of Arkansas for Medical Sciences, Little Rock, AR.

Tóm tắt

Abstract

Methylene blue has been in medicinal use for centuries and is best known as an antidotal treatment for acquired methemoglobinemia (MetHB). More recently, methylene blue has gained recognition for its efficacious use in the treatment of ifosfamide neurotoxicity and refractory vasoplegic shock in both the pediatric and adult critical care literature, extending its use beyond MetHB. Methylene blue’s mechanism of action is somewhat complex and based partly on its oxidizing capabilities, ironically the same mechanism that causes MetHB. This review will examine methylene blue’s use in the treatment of acquired MetHB and ifosfamide neurotoxicity and review the current literature regarding its role in critically ill pediatric and adult patients with refractory vasoplegic shock. Methylene blue’s pharmacologic actions, dosing, and adverse effects will also be discussed.

Từ khóa


Tài liệu tham khảo

2020, The story of nitric oxide, sepsis and methylene blue: a comprehensive pathophysiologic review, Am J Med Sci, 360, 329, 10.1016/j.amjms.2020.06.007

2016, Methylene blue: magic bullet for vasoplegia?, Anesth Analg, 122, 194, 10.1213/ANE.0000000000001045

2018, Intraoperative vasoplegia: methylene blue to the rescue, Curr Opin Anaesthesiol, 31, 43, 10.1097/ACO.0000000000000548

2015, A novel use of methylene blue in the pediatric ICU, Pediatrics, 136, e1030, 10.1542/peds.2014-3722

2014, Methylene blue used in the treatment of refractory shock resulting from drug poisoning, Clin Toxicol (Phila), 52, 63, 10.3109/15563650.2013.870343

2013, Methylene blue for distributive shock: a potential new use of an old antidote, J Med Toxicol, 9, 242, 10.1007/s13181-013-0298-7

2020, Methylene blue for refractory shock in children: a systematic review and survey practice analysis, Pediatr Crit Care Med, 21, e378, 10.1097/PCC.0000000000002295

2021, Methylene blue and ifosfamide-induced encephalopathy: myth or reality?, J Oncol Pharm Pract, 27, 143, 10.1177/1078155220971843

2006, Drug information rounds methylene blue for management of ifosfamide-induced encephalopathy, Ann Pharmacother, 40, 299, 10.1345/aph.1G114

2000, Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature, Br J Cancer, 82, 291, 10.1054/bjoc.1999.0917

2020, Vasopressor-sparing action of methylene blue in severe sepsis and shock: a narrative review, Adv Ther, 37, 3692, 10.1007/s12325-020-01422-x

2015, Improvement in hemodynamics after methylene blue administration in drug-induced vasodilatory shock: a case report, J Med Toxicol, 11, 460, 10.1007/s13181-015-0500-1

2006, Use of methylene blue in sepsis: a systematic review, J Intensive Care Med, 21, 359, 10.1177/0885066606290671

2020, Methylene blue administration for distributive shock states in critically ill children, Isr Med Assoc J, 22, 404